We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

Mon, 01st Jul 2019 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith, up 1.7%. The paper and packaging firm said it completed the sale of two packaging businesses in north west France and in Portugal to Memphis, Tennessee-based peer International Paper for EUR63 million. DS Smith said the sale honours the commitment made to the European Commission in relation to the clearance of its acquisition of Spanish packaging firm Europac, which completed in January. Last month, DS Smith had said financial 2019, which ended on April 30, was a "year of good delivery" overall, with "substantial" progress being made overseas and the integration of Europac was going well. Fellow packaging firms Smurfit Kappa and Mondi were up 2.6% and 1.7%, respectively. ----------FTSE 100 - LOSERS----------Fresnillo, down 2.9%. The Mexican gold miner was tracking spot gold prices lower, quoted at USD1,390.28 an ounce, down sharply from USD1,411.62 late Friday. Last week, gold had touched a six-year high of USD1,438.63. Additionally, Fresnillo on Monday said it has decided to align tax treatment for all of the company's underground mining operations, resulting in a USD8.0 million impact on profit for the six months to June-end. Shares in midcap gold miners Centamin and Hochschild Mining also were being hurt by the lower gold price, down 2.2% and 1.7%, respectively.----------International Consolidated Airlines Group, down 1.2%. Bernstein downgraded the airlines operator to Market Perform from Outperform. ----------FTSE 250 - WINNERS----------Future, up 9.0%. The digital media and publishing firm said full-year results will be ahead of expectations, underpinned by good audience growth within the Media division and the continued strong performance of recent acquisitions. The guidance was also attributed to a continuation of positive trends seen in the first half. Future's financial year ends September and will report annual results in November. "Future has a platform which enables it to monetise specialist content through a mixture of e-commerce, getting content users to click through to partnered retailers, events and online advertising. The plan is to feed newly-acquired assets into this platform. Newspaper and magazine publishers continue to battle falling sales and have struggled to get readers to pay for their relatively generic content, but consumers have shown a greater willingness to pay for specialist and niche content which they are unable to get elsewhere," said AJ Bell's Russ Mould.----------FTSE 250 - LOSERS----------John Laing Group, down 1.0%. Barclays started coverage on the infrastructure project investor at Equal Weight. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Tiziana Life Sciences, up 14%. The biotechnology company noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes. The phase two study of Teplizumab, an anti-CD3 antibody similar to Foralumab being developed by Provention Bio, was published in the New England Journal of Medicine. Type-1 diabetes is caused by the immune system's T cells attacking insulin-producing cells in the body. Anti-CD3 antibodies like Tiziana's Foralumab and Provention Bio's Teplizumab suppress the immune system to prevent this from happening. Teplizumab is derived from mice and was injected intravenously in patients whose relatives already have type 1 diabetes. Of the 76 patients evaluated, 72% were under 18. The patients were randomised to receive either a 14-day course of Teplizumab or placebo and tested at six-month intervals. At the end of the Teplizumab trial, 57% of participants treated with the drug had not developed diabetes compared to 28% on the placebo.----------OTHER MAIN MARKET AND AIM - LOSERS----------Hurricane Energy, down 17%. The oil and gas explorer said it will abandon and plug the Warwick Deep well after it did not produce at commercial rates. Hurricane had drilled the offshore North Sea well to 1,964 metres, with results indicating a 712-metre horizontal section of fractured basement reservoir. However, initial analysis suggests the well found a "poorly" connected part of the fracture network within the oil column, and the well produced at non-commercial rates. Following plugging and abandoning Warwick Deep, Hurricane will move the rig to the Lincoln Crestal wall, the second of three wells on the Greater Warwick Area.----------

More News
7 Feb 2019 11:40

Tiziana Life Sciences Non-Exec Director Riccardo Dalla-Favera Resigns

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday said Non-Executive Director Riccardo Dalla-Favera has resigned from his role."The company is grateful to Favera for his

Read more
3 Dec 2018 14:27

Tiziana completes patient enrolment in ongoing Milciclib study

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that patient enrolment in its ongoing Phase 2a clinical trial, known as CDKO-125A-010, was now completed.

Read more
3 Dec 2018 11:51

Tiziana Life Completes Patient Enrollment In Liver Cancer Trial

LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.The company explained that the

Read more
28 Nov 2018 12:19

Tiziana Life Sciences Begins First-In-Human Phase 1 Trial Of Foralumab

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it began the first in-human trial of Foralumab, a treatment for autoimmune diseases.The biotechnology company said the a

Read more
20 Nov 2018 12:53

Tiziana Life Sciences Prices ADS Offering, Raises GBP3.4 Million

LONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has priced its underwritten public offering in the US of 442,910 American Depositary Shares representing ordinary shares in

Read more
25 Sep 2018 13:43

Tiziana Life Seeks Listing Of ADS On Nasdaq Capital Market (ALLIPO)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has commenced underwritten public offering in the US of American Depositary Shares representing ordinary shares in the UK of

Read more
24 Sep 2018 12:37

Tiziana Half-Year Loss Unchanged; Gets US Approval For Foralumab Trial

LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday reported a flat loss in the first half of 2018 as expenses were broadly unchanged, while the biotechnology firm also announced that its

Read more
17 Aug 2018 11:39

DIRECTOR DEALINGS: Tiziana Life Chairman Associate Buys Shares

LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday that Panetta Partners Ltd, a company associated with Chairman Gabriele Cerrone, bought shares in the company worth acquired 469,766 a

Read more
16 Aug 2018 11:47

Tiziana seeks trial for multiple sclerosis 'game changer'

(Sharecast News) - Tiziana Life Sciences on Thursday submitted an application to initiate phase one clinical trials for a new treatment of neurodegenerative diseases to the US food and drug administration.

Read more
27 Jul 2018 11:14

Tiziana Life Sciences Files For IPO Of American Depositary Shares (ALLIPO)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday it filed a registration statement with the US Securities Exchange Commission for a proposed initial public offering of its American

Read more
16 May 2018 13:27

Tiziana Life Science Reports Progress In Milcicib Phase 2a Trial

LONDON (Alliance News) - Biotechnology company Tiziana Life Sciences PLC said Wednesday that the phase 2a trial of Milciclib safety and tolerability in patients with Metastatic Hepatocellular has

Read more
19 Apr 2018 14:44

Tiziana Raises GBP825,000 Through Placing Of 1 Million Shares (ALLISS)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Thursday it has raised GBP825,000 from the issue of 1.0 million new shares at a price of 80 pence per share.The cancer and autoimmune

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
16 Nov 2016 09:34

Tiziana Life Sciences makes breakthrough oral treatment for inflammatory diseases

(ShareCast News) - Tiziana Life Sciences, the clinical stage biotechnology company, announced that new data has demonstrated the potential of its novel oral therapy with foralumab for non-alcoholic steatohepatitis (NASH), diabetes and other life threatening inflammatory diseases. Oral efficacy in hu

Read more
18 Jul 2016 12:03

Tiziana Life looks for secrets of long life with new acquisition

(ShareCast News) - Tiziana Life Sciences has purchased key assets from Sardinia-based biobanking and genomics research company Shardna for €258,000, giving it access to the genetic data of nearly 13,000 people from the Ogliastra region, where life expectancy is high. The AIM-listed clinical stage bi

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.